Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 12, 2015, Pages 994-1003

  Blackler, Rory W ^a   De Palma, Giada ^a   Manko, Anna ^a,b   Da Silva, Gabriela J ^a,c   Flannigan, Kyle L ^a   Bercik, Premysl ^a   Surette, Michael G ^a   Buret, Andre G ^b   Wallace, John L ^b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSIDADE CAMILO CASTELO BRANCO   (Brazil)

Author keywords

Bile; Bleeding; Gastrointestinal; Microbiota; Proton pump inhibitors

Indexed keywords

NAPROXEN; NAPROXEN DERIVATIVE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; [2 (6 METHOXY NAPHTHALEN 2 YL)PROPIONIC ACID 4 THIOCARBAMOYL PHENYL ESTER]; 2-(6-METHOXY-NAPTHALEN-2-YL)-PROPIONIC ACID 4-THIOCARBAMOYL-PHENYL ESTER; HYDROGEN SULFIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RNA 16S;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE; BILIARY EXCRETION; CYTOTOXICITY; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG SAFETY; ENTERITIS; ENTEROHEPATIC CIRCULATION; ENTEROPATHY; IN VITRO STUDY; INTESTINAL BLEEDING; INTESTINE FLORA; INTESTINE INJURY; INTESTINE ULCER; MALE; NONHUMAN; NONSTEROID ANTIINFLAMMATORY DRUG INDUCED ENTEROPATHY; PATHOGENESIS; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; INFLAMMATION; INTESTINAL DISEASES; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HEPATOBILIARY ELIMINATION; HYDROGEN SULFIDE; INFLAMMATION; INTESTINAL DISEASES; MALE; NAPROXEN; PROTON PUMP INHIBITORS; RATS, WISTAR; RNA, RIBOSOMAL, 16S;

EID: 84932115969     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00066.2015     Document Type: Article

References (64)

1. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 82: 186-191, 2006.
2. Bartram AK, Lynch MD, Stearns JC, Moreno-Hagelsieb G, Neufeld JD. Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end illumina reads. Appl Environ Microbiol 77: 3846-3852, 2011.
3. Beck WS, Schneider HT, Dietzel K, Nuernberg B, Brune K. Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physiochemical and biochemical factors involved. Arch Toxicol 64: 210-217, 1990.
4. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 29: 625-651, 2005.
5. Blackler RW, Gemici B, Manko A, Wallace JL. NSAID-enteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol 19: 11-16, 2014.
6. Blackler RW, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, Wallace JL. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol 172: 992-1004, 2015.
7. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinalsparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 7: e35196, 2012.
8. Boughton-Smith NK, Wallace JL, Whittle BJ. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions 25: 115-123, 1988.
9. Brune K, Dietzel K, Nurnberg B, Schneider HT. Recent insight into the mechanism of gastrointestinal tract ulceration. Eur J Rheumatol Inflamm 9: 8-14, 1987.
10. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335-336, 2010.
11. Dalby AB, Frank DN, St Amand AL, Bendele AM, Pac NR. Cultureindependent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl Environ Microbiol 72: 6707-6715, 2006.
12. Dial EJ, Darling RL, Lichtenberger LM. Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury. J Gastroenterol Hepatol 23: e384-e389, 2008.
13. Dice LR. Measures of the amount of ecologic association between species. Ecology 26: 297-302, 1945.
14. Dietschy JM. Mechanisms for the intestinal absorption of bile acids. J Lipid Res 9: 297-309, 1968.
15. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill JP, Masliah J, Geaugerie L, Cosnes J, Chasouilleres O, Poupon R, Wolf C, Mallet JM, Langella P, Trugnan G, Sokol H, Seksik P. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62: 531-539, 2013.
16. Elliot SN, Buret A, McKnight W, Miller MJ, Wallace JL. Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol Gastrointest Liver Physiol 275: G425-G432, 1998.
17. Elsheikh W, Blackler RW, Flannigan KL, Wallace JL. Enhanced chemopreventative effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide 41: 131-137, 2014.
18. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest 51: 43-51, 2004.
19. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159: 2647-2658, 1999.
20. Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 81: 291-298, 2007.
21. Kent TH, Cardelli RM, Stamler FW. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 54: 237-245, 1969.
22. Lagoutte E, Mimoun S, Andriamihaja M, Chaumontet C, Blachier F, Bouillaud F. Oxidation of hydrogen sulfide remains a priority of mammalian cells and causes reverse electron transfer in colonocytes. Biochim Biophys Acta 1797: 1500-1511, 2010.
23. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Alonso- Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Munoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 104: 1633-1641, 2009.
24. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 15: 474-479, 2012.
25. Lichtenberger LM, Phan T, Okabe S. Aspirin’s ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol 62: 491-496, 2011.
26. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 341: 447-454, 2012.
27. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 8: 504-508, 2010.
28. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMB Net J 17: 10-12, 2011.
29. Martinez-Augustin O, Sanchez de Medina F. Intestinal bile acid physiology and pathophysiology. World J Gastroenterol 14: 5630-5640, 2008.
30. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics 13: 31, 2012.
31. Motta JP, Flannigan KL, Agbor TA, Beatty JK, Blackler RW, Workentine ML, Da Silva GJ, Wang R, Buret AG, Wallace JL. Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis 21: 1006-1017, 2015.
32. Park AJ, Collins J, Blennerhassett PA, Ghia JE, Verdu EF, Bercik P, Collins SM. Altered colonic function and microbiota profile in a mouse model of chronic depression. Neurogastroenterol Motil 25: 733-e575, 2013.
33. Petruzzelli M, Vacca M, Moschetta A, Sasso RC, Palasciano G, van Erpecum KJ, Palasciano G, van Berge-Henegouwen GP, Moschetta A, Portincasa P. Intestinal mucosal damage caused by non-steroidal antiinflammatory drugs: role of bile salts. Clin Biochem 40: 503-510, 2007.
34. Quaroni A, Wands J, Trelstad RL, Isselbacher KJ. Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol 80: 248-265, 1979.
35. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109-117, 1997.
36. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44: 28-35, 2014.
37. Satoh H, Amagase K, Takeuchi K. Exacerbation of nonsteroidal antiinflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 343: 270-277, 2012.
38. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z. Prevention of ulcers by esomeprazole in at-risk patients using nonselective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101: 701-710, 2006.
39. Seitz S, Boelsterli UA. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115: 1476-1482, 1998.
40. Shindo K, Fukumura M. Effect of H2-receptor antagonists on bile acid metabolism. J Investig Med 43: 170-177, 1995.
41. Shindo K, Machida M, Fukumura M, Koide K, Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut 42: 266-271, 1998.
42. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 41: 344-353, 1997.
43. Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, Wallace JL. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol 50: 387-393, 2015.
44. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried M. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 39: 54-59, 1996.
45. Treinen-Moslen M, Kanz MF. Intestinal tract injury by drugs: importance of metabolite delivery by yellow bile road. Pharmacol Ther 112: 649-667, 2006.
46. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 40: 553-560, 1996.
47. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection; why doesn’t the stomach digest itself? Physiol Rev 88: 1547-1565, 2008.
48. Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 165: 67-74, 2012.
49. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 19: 1861-1876, 2013.
50. Wallace JL. Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci 58: 3088-3093, 2013.
51. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, Mac- Naughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115: 101-109, 1998.
52. Wallace JL, Blackler RW, Chan MV, Da Silva GJ, Elsheikh W, Flannigan KL, Gamaniek I, Manko A, Wang L, Motta JP, Buret AG. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal 22: 398-410, 2015.
53. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB- 346). Br J Pharmacol 159: 1236-1246, 2010.
54. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119: 706-714, 2000.
55. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322, 2011.
56. Ward J. Hierarchical grouping to optimize an objective function. J Am Statist Assoc 58: 236-244, 1963.
57. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: 181-187, 2008.
58. Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis 45: 390-395, 2013.
59. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 58: 772-780, 1970.
60. Whelan FJ, Verschoor CP, Stearns JC, Rossi L, Luinstra K, Loeb M, Smieja M, Johnstone J, Surette MG, Bowdish DM. The loss of topography in the microbial communities of the upper respiratory tract in the elderly. Ann Am Thorac Soc 11: 513-521, 2014.
61. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 23: 3-10, 2006.
62. Yamada T, Hoshino M, Hayakawa T, Kamiya Y, Ohhara H, Mizuno K, Yamada H, Nakazawa T, Inagaki T, Uchida A, Miyaji M, Takeuchi T. Bile secretion in rats with indomethacin-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 270: G804-G812, 1996.
63. Zhao Y, Encinosa W. Hospitalizations for Gastrointestinal Bleeding in 1998 and 2006: Statistical Brief #65. Health Care Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research, 2008.
64. Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 298: G722-G731, 2010.